New Treatments for AML Remain Elusive, But Researchers Are UndeterredLauren M. Green
Meanwhile, there are still a large number of patients without sensitive driven mutations who are not available for TKI treatments [36]. Therefore, it is particularly important to find new therapeutic targets for NSCLC patients with different driven mutations or with TKI resistance. In recent years,...
“With all of the tools available to us today, as clinicians, we are really relying on cross-trial comparisons and safety cross-trial comparisons to guide our treatments. So, if we come back to the clinical dilemma that we all face today— what do we do with that [patient ...
Unfortunately, available Chokα inhibitors also have toxic side-effect and are not approved for use in patients. Hopefully, this research might encourage screening for safe drugs interfering with these pathways and contribute the development of new treatments for AITL....
A strength of Evolving treatment patterns and outcomes in older AML: changing everything to change nothing? is documenting the suspected increasing use of non-intensive induction therapy in persons age ≥60 years from 1% 1999 to 2006 to 23% from 2007, when azacytidine and decitabine became ...
Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise ...
It's been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
including the downstream effects of 2-HG, CIMP, and histone modifications; further investigation will be needed to clarify the role of each of these factors in tumorigenesis, the effects on the vulnerability of the tumor to other treatments such as chemotherapy, and their impact on other crucial...
With advances in modern biotechnology, well-designed novel antibodies are finally paving the way for successful treatments of various cancers, including precise tumor immunotherapy, in the clinic. Antibody-based cancer therapy Introduction Over the past 30 years, therapeutic antibodies have revolutionized ...
Trophoblast cell surface antigen 2 (Trop2) is considered to be an attractive therapeutic target in cancer treatments. We previously generated a new humanized anti-Trop2 antibody named hIMB1636, and designated it as an ideal targeting carrier for cancer t